204 completed, 63 unknown, 43 terminated, 41 recruiting. 407 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 407 | Completed 204, Unknown 63, Terminated 43, Recruiting 41, Not yet recruiting 25, Withdrawn 18, Active not recruiting 11, Enrolling by invitation 2 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis High dose budesonide rectal foam, Low dose budesonide rectal foam, Matching placebo rectal foam - Ulcerative Colitis | Phase 4 | Not yet recruiting | Bausch Health Americas, Inc. | 100 | 2029-06-01 | 2026-10-06 |
| ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery 5-ASA, Placebo - Ulcerative Colitis (UC), Pouchitis | Phase 4 | Not yet recruiting | University Hospital, Linkoeping | 110 | 2027-04-01 | 2026-08-19 |
| Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-center Stepped Wedge Cluster Randomized Study Irrigation with PVI, Usual care - Acute, Perforated Appendicitis | Phase 4 | Not yet recruiting | The University of Texas Health Science Center, Houston | 1750 | 2027-03-01 | 2025-02-10 |
| Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis treatment withdrawal - Ulcerative Colitis in Remission | Phase 4 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 224 | 2027-01-01 | 2026-07-22 |
| MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula | Phase 4 | Not yet recruiting | Icahn School of Medicine at Mount Sinai | 50 | 2026-12-01 | 2026-08-24 |
| FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab - Ulcerative Colitis (UC) | Phase 4 | Not yet recruiting | University Hospital, Clermont-Ferrand | 240 | 2026-12-01 | 2026-10-21 |
| Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose Upadacitinib - Ulcerative Colitis (UC) | Phase 4 | Not yet recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 100 | 2026-11-15 | 2026-10-29 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Vonoprazan High-Dose Dual VS Levofloxacin Concomitant Vonoprazan, Levofloxacin 500mg - Helicobacter Pylori Infection, Peptic Ulcer Disease | Phase 4 | Not yet recruiting | Damascus Hospital | 150 | 2026-11-01 | 2026-06-03 |
| Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Upadacitinib - UC - Ulcerative Colitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 50 | 2026-10-15 | 2026-09-24 |
| Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Risankizumab - Crohn Disease, Perianal Fistula | Phase 4 | Recruiting | Yuki Horio | 25 | 2026-10-01 | 2026-10-23 |
| Combination CurQD and Vedolizumab in Ulcerative Colitis CurQD, Placebo, Vedolizumab - Ulcerative Colitis | Phase 4 | Not yet recruiting | Ryan C Ungaro | 160 | 2026-10-01 | 2026-10-05 |
| PPI Dosing Per CYP2C19 Genotype CYP2C19 based dosing Proton Pump Inhibitors, Conventional proton pump inhibitor dose - Gastroesophageal Reflux Disease With Esophagitis | Phase 4 | Not yet recruiting | University of Florida | 200 | 2026-10-01 | 2026-09-28 |
| Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® TyboWe® Adalimumab Injection - Crohn's Disease | Phase 4 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 50 | 2026-09-23 | 2026-09-24 |
| Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease Vancomycin (POC), Fidaxomicin - Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection | Phase 4 | Not yet recruiting | Brigham and Women's Hospital | 60 | 2026-09-01 | 2025-11-03 |
| Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) Tirzepatide, Loperamide, Diphenoxylate/Atropine - Pouch, Ileal, Pouches, Ileoanal | Phase 4 | Not yet recruiting | University of North Carolina, Chapel Hill | 20 | 2026-09-01 | 2026-08-10 |
| INSIGHT-IBD Pragmatic Study Mirikizumab, Anti-TNF agents, anti-integrin antibodies - Ulcerative Colitis (UC), Crohn Disease (CD) | Phase 4 | Enrolling by invitation | Specialty Networks Research. | 400 | 2026-08-12 | 2026-10-29 |
| A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative | Phase 4 | Recruiting | Janssen Research & Development, LLC | 10 | 2026-08-07 | 2026-10-05 |
| A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication Mirikizumab - Lactation, Inflammatory Bowel Disease | Phase 4 | Recruiting | Eli Lilly and Company | 14 | 2026-08-05 | 2026-09-08 |
| Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC Etrasimod, mesalazine - Etrasimod, Mesalazine | Phase 4 | Not yet recruiting | Sir Run Run Shaw Hospital | 320 | 2026-07-31 | 2026-08-24 |
Showing 20 of 407. Sign in to see all of them.
Crohn Disease (150) · Colitis, Ulcerative (127) · Inflammatory Bowel Diseases (80) · Appendicitis (31) · Gastritis (19) · Diarrhea (13) · Eosinophilic Esophagitis (11) · Mucositis (11) · Diverticulitis (10) · Peptic Ulcer (10) · Dyspepsia (9) · Esophagitis, Peptic (9) · Enterocolitis, Pseudomembranous (7) · Gastroesophageal Reflux (7)
Digestive System Diseases (405) · Gastrointestinal Diseases (404) · Intestinal Diseases (348) · Inflammatory Bowel Diseases (188) · Colonic Diseases (137) · Colitis (126) · Pathological Conditions, Signs and Symptoms (68) · Infections (51) · Signs and Symptoms (42) · Pathologic Processes (33) · Cecal Diseases (31) · Stomach Diseases (31) · Intraabdominal Infections (30) · Signs and Symptoms, Digestive (29)
Infliximab (42) · vedolizumab (32) · Adalimumab (22) · Mesalamine (17) · Azathioprine (14) · Metronidazole (14) · Amoxicillin (13) · Esomeprazole (10) · Ustekinumab (10) · golimumab (10) · Bismuth (8) · Clarithromycin (8) · Methotrexate (7) · Prednisone (7) · mirikizumab (7)
Takeda (15) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (14) · Xijing Hospital of Digestive Diseases (10) · Sixth Affiliated Hospital, Sun Yat-sen University (6) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (5) · Alimentiv Inc. (5) · Universitaire Ziekenhuizen KU Leuven (5) · University of North Carolina, Chapel Hill (5) · Children's Hospital of Fudan University (4) · Medical University of Warsaw (4) · Merck Sharp & Dohme LLC (4) · Prof. Arie Levine (4) · University of Wisconsin, Madison (4) · Asan Medical Center (3) · Bausch Health Americas, Inc. (3)
United States (117) · Canada (39) · France (36) · China (34) · Italy (27) · Netherlands (23) · Belgium (22) · United Kingdom (20) · Israel (18) · Spain (18) · South Korea (16) · Denmark (14) · Germany (14) · Poland (11) · Australia (10)
Arie Levine, MD (5) · Yongquan Shi, Ph. D (4) · Brian G Feagan, MD (3) · Dan Turner, MD, PhD (3) · Ron Shaoul, MD (3) · Vipul Jairath, MD (3) · Ying Huang (3) · Batia Weiss, MD (2)
PMID 40013523, PMID 40357993, PMID 10049409, PMID 10896917, PMID 12432298, PMID 14762782, PMID 1499440, PMID 15058524, PMID 15168373, PMID 15555725, PMID 16116317, PMID 16279893, PMID 16329022, PMID 16393226, PMID 16393228, PMID 16500392, PMID 16611269, PMID 1669678, PMID 17058158, PMID 17058159, PMID 17305763, PMID 17308939, PMID 17593171, PMID 17762967, PMID 17919504, PMID 18295023, PMID 18564124, PMID 18721738, PMID 18723709, PMID 19109962, PMID 19116333, PMID 19135997, PMID 19209273, PMID 19253787, PMID 1948581, PMID 19535182, PMID 19577749, PMID 19960205, PMID 20135748, PMID 20505508, PMID 20670293, PMID 20920599, PMID 21443962, PMID 21541799, PMID 21547879, PMID 21556992, PMID 21633832, PMID 21788756, PMID 2179031, PMID 2179802
2014 (8), 2025 (5), 2015 (4), 2009 (3), 2016 (3), 2017 (3), 2018 (2), 2019 (2), 2023 (2), 2008 (1), K12TR004908 (1), K24DK078228 (1), R01DK059961 (1), R01DK101856 (1), R01DK125495 (1)